Relmada Therapeutics (RLMD) Gross Profit (2012 - 2013)
Relmada Therapeutics (RLMD) reported Gross Profit of $164.0 for Q4 2013, down 45.15% year-over-year from $299.0 in Q4 2012, and down 47.44% quarter-over-quarter from $312.0 in Q2 2013.
Relmada Therapeutics (RLMD) Gross Profit (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of Gross Profit data on file, last reported at $164.0 in Q4 2013.
- Gross Profit for Q4 2013 came in at $164.0, down 45.15% year-over-year; the trailing twelve-month figure through Nov 2013 was $958.0 (changed N/A YoY), and the FY2013 annual result was $1093.0, down 48.97% from the prior year.
- Gross Profit eased to $164.0 in Q4 2013 per RLMD's latest filing, from $312.0 in the prior quarter.
- Over five years, Gross Profit peaked at $517.0 in Q3 2012 and troughed at $108.0 in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | 164.00 |
| Nov 30, 2013 | 164.00 |
| May 31, 2013 | 312.00 |
| May 31, 2013 | 312.00 |
| Feb 28, 2013 | 482.00 |
| Feb 28, 2013 | 482.00 |
| Nov 30, 2012 | 299.00 |
| Nov 30, 2012 | 299.00 |
| Aug 31, 2012 | 517.00 |
| Aug 31, 2012 | 517.00 |
| May 31, 2012 | 108.00 |
| May 31, 2012 | 108.00 |